1. Home
  2. Live Updates
  3. Gemcitabine

Gemcitabine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gemcitabine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gemcitabine Today - Breaking & Trending Today

TAR-200 Monotherapy Has 82.8% Complete Response Rate in BCG-Unresponsive HR-NMIBC

Updated findings from SunRISe-1 also showed that all but 1 responder achieved complete response within 12 weeks of treatment with the targeted gemcitabine delivery system. ....

United States , Joseph Jacob , Bernard Chantal , European Society For Medical Oncology , American Urological Association , European Association Of Urology , Bacillus Calmette Gu , Upstate Medical , European Society , Medical Oncology , European Association , Bacillus Calmette , Sunrise 1 , Tar 200 , Bladder Cancer ,

Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant

Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas. ....

United States , Jeremyl Ramdial , University Of Texas Md Anderson Cancer Center , Division Of Cancer Medicine , Department Of Stem Cell Transplantation , Stem Cell Transplantation , Cellular Therapy , Cancer Medicine , Cancer Center , The University Of Texas Md Anderson Cancer Center , Lofarabine And Busulfan , Patients With Aggressive Lymphomas ,

Dr Tripathi on the NEMIO Trial of Durvalumab Plus Chemo With/Without Tremelimumab in MIBC

Abhishek Tripathi, MD, discusses the phase 1/2 NEMIO trial of durvalumab/chemotherapy with/without tremelimumab in muscle-invasive bladder cancer. ....

Abhishek Tripathi , Onclive Tv , Urothelial Cancer , Hase 3 Checkmate 901 Trial ,

Dr Tripathi on the Use of Frontline Nivolumab/Chemotherapy in Urothelial Carcinoma

Abhishek Tripathi, MD, discusses the significance of data from the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma. ....

Abhishek Tripathi , Onclive Tv , Urothelial Cancer , Hase 3 Checkmate 901 Trial ,

IPIAD augments standard therapy for pancreatic ductal adenocarcinoma

A new research perspective was published in Oncoscience (Volume 11) on February 7, 2024, entitled, "IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone." ....

Richarde Kast , Study Center ,